GENERAL CHARACTERISTICS
Lipid-lowering drugs, multi-agents. HMG-CoA reductase ihibitors. ATC code С10А А01.
Indications to Use:
Hypercholesterolemia: treatment of primary hypercholesterolemia or mixed dyslipidemia, as a supplement to a diet, when the response to the diet and other drug-free treatments (e.g., bodily exercises, weight loss) is not enough.
Treatment of homozygous familial hypercholesterolemia, as a supplement to diet and other lipid-lowering therapy (e.g., low density lipids apheresis) or if such treatment methods are not appropriate.
Cardiovascular disease prevention: reduction of cardiovascular mortality and morbidity in patients with obvious atherosclerotic cardiovascular disease or diabetes mellitus with normal or elevated cholesterol levels, as an adjunctive therapy to correct other risk factors and in addition to other cardioprotective therapy.
Vasostat
-
$22 -
GENERAL CHARACTERISTICS Lipid-lowering drugs, multi-agents. HMG-CoA reductase ihibitors. ATC code С10А А01. Indications to Use: Hypercholesterolemia: treatment of primary hypercholesterolemia or mixed dyslipidemia, as a supplement to a diet, when the response to the diet and other drug-free treatments (e.g., bodily exercises, weight loss) is not enough. Treatment of homozygous familial hypercholesterolemia, as a supplement to diet and other lipid-lowering therapy (e.g., low density lipids apheresis) or if such treatment methods are not appropriate. Cardiovascular disease prevention: reduction of cardiovascular mortality and morbidity in patients with obvious atherosclerotic cardiovascular disease or diabetes mellitus with normal or elevated cholesterol levels, as an adjunctive therapy to correct other risk factors and in addition to other cardioprotective therapy.$13 -
GENERAL CHARACTERISTICS Lipid-lowering drugs, multi-agents. HMG-CoA reductase ihibitors. ATC code С10А А01. Indications to Use: Hypercholesterolemia: treatment of primary hypercholesterolemia or mixed dyslipidemia, as a supplement to a diet, when the response to the diet and other drug-free treatments (e.g., bodily exercises, weight loss) is not enough. Treatment of homozygous familial hypercholesterolemia, as a supplement to diet and other lipid-lowering therapy (e.g., low density lipids apheresis) or if such treatment methods are not appropriate. Cardiovascular disease prevention: reduction of cardiovascular mortality and morbidity in patients with obvious atherosclerotic cardiovascular disease or diabetes mellitus with normal or elevated cholesterol levels, as an adjunctive therapy to correct other risk factors and in addition to other cardioprotective therapy.$11